Evidence map›Paper›PMID 38135691›Full record

ArticleNature communications2023

Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac disease.

Yuu Okura, Yuri Ikawa-Teranishi, Akihiko Mizoroki, Noriyuki Takahashi, Takashi Tsushima, Machiko Irie, Zulkarnain Harfuddin, Momoko Miura-Okuda, Shunsuke Ito, Genki Nakamura and 20 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 2 institutions in 2 countries.

Yuu OkuraTranslational Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.ORCID 0000-0002-6949-8105
Yuri Ikawa-TeranishiResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.
Akihiko MizorokiResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.
Noriyuki TakahashiChugai Pharmabody Research Pte. Ltd., Singapore, Singapore.ORCID 0000-0001-8954-6998
Takashi TsushimaChugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Machiko IrieResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.
Zulkarnain HarfuddinChugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Momoko Miura-OkudaChugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Shunsuke ItoTranslational Research Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.ORCID 0000-0002-6396-4822
Genki NakamuraResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.
Hiroaki TakesueResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.ORCID 0000-0001-8585-5494
Yui OzonoResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.
Masamichi NishiharaResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.
Kenta YamadaResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.
Siok Wan GanChugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Akira HayasakaResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.
Shinya IshiiResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.
Tetsuya WakabayashiResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.ORCID 0000-0001-9547-1291
Masaru MuraokaResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.
Nishiki NagayaResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.
Hiroshi HinoResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.
Takayuki NemotoTranslational Research Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.
Taichi KuramochiResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.
Takuya TorizawaResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.ORCID 0000-0001-7537-6123
Hideaki ShimadaChugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Takehisa KitazawaResearch Division, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan.
Makoto OkazakiChugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Junichi NezuR&D Portfolio Management Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.ORCID 0000-0003-0476-1264
Ludvig M SollidDepartment of Immunology, Oslo University Hospital, Oslo, Norway.ORCID 0000-0001-8860-704X
Tomoyuki IgawaTranslational Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan. igawatmy@chugai-pharm.co.jp.ORCID 0000-0003-0097-8220
Chugai Pharma (United States) · USOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In human celiac disease (CeD) HLA-DQ2.5 presents gluten peptides to antigen-specific CD4

Indexed as

Celiac DiseaseGlutensAnimalsAntibodies, NeutralizingEpitopesHLA-DQ AntigensHumansMiceMice, TransgenicPeptidesRabbitsAntibodies, NeutralizingEpitopesGlutensHLA-DQ AntigensPeptides

Identifiers

PMID38135691
PMCPMC10746718
OpenAlexW4390105567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.